Near-infrared electroluminescence has attracted considerable attention due to its ability to penetrate biological tissues more effectively than visible light, making it an ideal candidate for non-invasive bioimaging. However, a pervasive challenge has been the efficiency roll-off at high current densities, which severely limits device performance and lifespan. This efficiency degradation, often referred to as “roll-off,” is primarily attributed to processes such as triplet-triplet annihilation (TTA) and charge imbalance, which become pronounced under operational stresses.

The research team’s breakthrough centers on the introduction of a specialized ion agent that stabilizes the charge balance and suppresses the non-radiative decay mechanisms responsible for efficiency roll-off. By precisely engineering the ionic environment within the electroluminescent materials, they successfully enhanced the emission efficiency at higher operational currents without sacrificing device stability. This fundamental improvement marks a significant leap towards the realization of high-performance NIR light-emitting diodes (LEDs).

Technically, the ion agent functions by modulating the local electric field and facilitating the controlled injection and transport of charge carriers within the emissive layer. This regulation minimizes the formation of exciton quenching sites and reduces the likelihood of exciton-exciton interactions that typically degrade luminescent efficiency. The result is a more robust electroluminescent response that can sustain higher brightness levels necessary for practical applications.

One of the key implications of this technology lies in biomedical imaging, where enhanced NIR emission can provide clearer, deeper tissue images. Traditional imaging methods often struggle with light penetration or induce photodamage, but the improved devices enabled by this ion agent could overcome these limitations. This will potentially lead to safer, real-time imaging modalities for diagnostics and therapeutic monitoring, further integrating optical technologies into clinical practice.

Beyond bioimaging, the research opens new avenues in the domain of information encryption. The unique electroluminescence characteristics facilitated by the ion additive can be harnessed for creating optical security features that are difficult to replicate or decode. These features could serve as the foundation for advanced anti-counterfeiting measures and secure data storage devices that operate at the photon level.

The extensive experimental analysis conducted by the authors included spectroscopic characterization and stability testing under various operational conditions, confirming the durability and reliability of the ion-enhanced NIR emitters. Notably, the devices maintained high external quantum efficiencies (EQE) even at increased drive currents, a critical metric for commercial adoption.

From a materials science perspective, the synthesis and integration of the ion agent were meticulously optimized to ensure compatibility with existing organic and inorganic NIR-emitting systems. This compatibility facilitates scalability and paves the way for mass production without needing extensive redesigns of current device architectures. Thus, the innovation holds promise not only scientifically but also from a manufacturing and economic standpoint.

The study’s approach is distinguished by its multidisciplinary methodology, combining insights from photophysics, organic chemistry, and device engineering. Through this comprehensive effort, the team elucidated the underlying mechanisms contributing to efficiency roll-off and developed a viable countermeasure that could become a standard component in next-generation photonic devices.

Moreover, the research contributes to the broader understanding of exciton dynamics within electroluminescent materials, a subject that underpins many modern optoelectronic applications. By demonstrating the practical benefits of ionic modulation, the findings encourage further exploration into ion-based tuning of electronic properties in diverse luminescent systems.

Looking ahead, the potential of this ion agent extends to other technologically relevant wavelengths beyond the near-infrared. The principles demonstrated could be adapted to improve visible light-emitting devices or even ultraviolet emitters, thereby enhancing a wide spectrum of applications from displays to photocatalysis.

While the current work focuses on proof-of-concept devices, the researchers emphasize the pathway towards integrating this technology into flexible and wearable formats. Such integration could revolutionize portable health monitoring devices, providing continuous and non-invasive diagnostic capabilities enhanced by superior NIR illumination.

Additionally, the demonstrated long-term operational stability addresses a critical concern in the field of organic electronics, where device degradation often limits lifespan and application scope. By substantially mitigating efficiency roll-off, these ion-enhanced devices could achieve commercial viability previously unattainable with conventional materials.

The publication also signals an important trend in optical materials research, spotlighting the role of ion engineering as a versatile and powerful tool for performance optimization. This approach complements other strategies such as molecular design and interface engineering, offering a modular pathway to improve device functionalities.

This breakthrough arrives at a pivotal moment as the demand for advanced bioimaging technologies and secure optical communication systems intensifies globally. By bridging fundamental science and application-driven innovation, the research by Yang et al. sets a new benchmark in electroluminescent device engineering.

In summary, the integration of the novel ion agent into near-infrared emitters represents a transformative advancement with significant implications across bioimaging and data security industries. The mitigation of efficiency roll-off not only enhances the brightness and durability of these devices but also unlocks new functional possibilities, heralding a new era for practical electroluminescent technologies.

Subject of Research: Near-infrared electroluminescence and mitigation of efficiency roll-off for applications in bioimaging and information encryption.

Article Title: Ion agent mitigates efficiency roll-off in near-infrared electroluminescence for practical bioimaging and information encryption.

Article References:
Yang, T., Wang, Y., Liu, ZS. et al. Ion agent mitigates efficiency roll-off in near-infrared electroluminescence for practical bioimaging and information encryption. Light Sci Appl 15, 221 (2026). https://doi.org/10.1038/s41377-026-02237-1

Image Credits: AI Generated

DOI: 10.1038/s41377-026-02237-1

Pancreatic cancer remains a formidable challenge due to its rapid progression and late diagnosis, which often leaves clinicians with limited tools for predicting how individual patients will fare. Conventional methods rely heavily on clinical judgment and basic imaging assessments, typically falling short in prognostic detail. Recognizing this gap, researchers embarked on a rigorous investigation spanning a decade, analyzing data drawn from 880 patients treated across two major hospitals between 2013 and 2023.

Central to this study was the use of portal venous phase contrast-enhanced computed tomography (CT) scans, which provide detailed visualizations of the pancreatic tumors. Two experienced physicians meticulously delineated tumor regions of interest (ROIs), ensuring high-quality input data integral for precise feature extraction. From these ROIs, an extensive set of 1,037 radiomic features was computed, encompassing a vast array of quantitative descriptors such as texture, shape, and intensity metrics that describe tumor heterogeneity invisible to the naked eye.

Given the overwhelming volume and complexity of these features, the research team employed principal component analysis (PCA) for dimensionality reduction, helping to distill the most critical patterns. LASSO regression further fine-tuned this selection, isolating variables most strongly associated with survival outcomes. This rigorous feature selection process ensured that the resulting radiomics model would robustly handle the prediction of overall survival while accounting for the censored nature of clinical survival data.

Parallel to the radiomics approach, the investigators developed a 3D-DenseNet deep learning model designed to extract sophisticated imaging features directly from the ROI-based 3D image volumes. DenseNet architecture, known for efficient feature reuse and gradient flow, was leveraged to capture nuanced spatial relationships within the tumor, beyond traditional handcrafted features. This neural network was trained to predict survival status at distinct time points—1-year, 2-year, and 3-year—offering temporal granularity vital for clinical decision-making.

Crucially, the innovation lies in the fusion of these two distinct modalities. The study integrated radiomic features, deep learning outputs, and baseline clinical data into composite models using several machine learning classifiers including logistic regression, random forest, support vector machine, and decision tree algorithms. The fusion was framed as a binary classification task, aiming to determine survival status at targeted temporal milestones, a practical scenario for oncologists tailoring treatment plans.

Performance evaluation revealed that while each unimodal model exhibited strong predictive capabilities, the fusion model consistently outshone them. In the test cohort, the fusion model achieved remarkable area under the curve (AUC) values—0.87 for 1-year, 0.92 for 2-year, and an impressive 0.94 for 3-year survival prediction. Accuracies also peaked at 0.84, 0.86, and 0.89 respectively, marking substantial improvements over the radiomics and 3D-DenseNet models alone.

A remarkable aspect of the study was the exploration of feature contributions within the fusion model, unveiling that deep learning features extracted via the 3D-DenseNet had the most influential role in survival predictions. Radiomic features carried significant weight as well, while clinical variables complemented these imaging-derived data, collectively enabling a nuanced assessment of disease prognosis that surpasses traditional standards.

The authors demonstrated the clinical utility of their model by stratifying patients into high-risk and low-risk categories based on the fusion model’s predictions. Kaplan-Meier survival analyses and Log-rank tests underscored statistically significant differences in overall survival between these groups, emphasizing the model’s potential to guide personalized therapeutic strategies and optimize resource allocation in clinical oncology.

This study represents a significant leap forward in oncologic imaging and machine learning integration, positioning radiomics and 3D deep learning not as competing entities but as synergistic tools for enhanced prognostication. By blending detailed tumor characterization with powerful computational pattern recognition, the fusion model embodies the next frontier of precision medicine in pancreatic cancer.

Moreover, the methodological rigor and multi-institutional nature of the dataset lend robustness and generalizability to the findings, suggesting that such fusion models could be adapted and validated across diverse clinical settings. Future efforts may aim to incorporate additional biomarkers, such as genomic or serum-based data, further enriching predictive power and mechanistic insights.

The implications for patient care are profound. Accurate survival predictions enable clinicians to tailor interventions, balancing aggressive treatments with palliative care when appropriate, thereby improving quality of life and optimizing clinical outcomes. Furthermore, such models can inform clinical trial designs by identifying suitable candidates who might benefit most from investigational therapies.

In conclusion, the fusion of radiomics and 3D deep learning holds immense promise for transforming pancreatic cancer prognosis. This study illuminates a path toward harnessing complex image-derived data with artificial intelligence to unlock predictive insights previously unattainable through conventional means. As computational methods continue to evolve, their integration into clinical oncology workflows becomes imperative for advancing personalized medicine.

The development of this fusion prognostic model heralds a paradigm shift, demonstrating that the convergence of technology and medicine can yield powerful new tools to confront one of the most lethal cancer types. With continued research and clinical validation, such innovations may soon move from the pages of scientific journals into everyday clinical practice, offering renewed hope for patients battling pancreatic cancer worldwide.

Subject of Research: Prognostic prediction models in pancreatic cancer combining radiomics and 3D deep learning approaches.

Article Title: Development of a radiomics-3D deep learning fusion model for prognostic prediction in pancreatic cancer

Article References:
Dou, Z., Lu, C., Shen, X. et al. Development of a radiomics-3D deep learning fusion model for prognostic prediction in pancreatic cancer. BMC Cancer 25, 1612 (2025). https://doi.org/10.1186/s12885-025-14889-0

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14889-0